Want to see HK:1228 full AI Analyst Report?
1228 Stock Chart & Stats
HK$2.52
<HK$0.01(5.93%)
At close: 4:00 PM EST
HK$2.52
<HK$0.01(5.93%)
Day’s Range― - ―
52-Week RangeHK$0.96 - HK$3.50
Previous CloseN/A
Volume661.00K
Average Volume (3M)5.03M
Market Cap
HK$1.19B
Enterprise ValueHK$1.25K
Total Cash (Recent Filing)HK$66.63M
Total Debt (Recent Filing)HK$16.08M
Price to Earnings (P/E)36.1
Beta1.06
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding597,443,360
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)-3.32
Price to Sales (P/S)22.72
P/FCF Ratio-29.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
Bulls Say, Bears Say
Bulls Say
Specialist Rare-disease FocusA clear strategic focus on rare diseases and underserved conditions creates a durable niche with higher pricing power, lower generic competition, and attractive partner interest. The in-licensing/commercialization model reduces early discovery risk and supports recurring licensing and product-sale revenue opportunities over time.
High Gross MarginsSustained gross margins in the low-60s to low-70s suggest structurally favorable unit economics for marketed specialty medicines. Once fixed R&D and SG&A are absorbed by higher sales, these margins can drive durable operating leverage, improving cash generation potential as revenue scale is achieved.
Debt Reduction And Improved BurnLower debt and reduced cash burn materially de-risk the capital structure, extending runway for clinical and commercialization milestones. This structural improvement lessens near-term refinancing pressure and gives management more optionality to pursue partnerships or selective commercial investment.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates the business cannot self-fund development and commercialization. This creates a structural reliance on external financing or partnerships, raising dilution and execution risk and limiting ability to independently scale operations over the next several quarters.
Negative Shareholders' EquityPersistent negative shareholders' equity materially weakens financial flexibility and heightens refinancing and counterparty risk. This structural balance-sheet impairment can constrain borrowing, partner contracting, and strategic transactions until equity is restored via sustained profits or fresh capital.
Revenue Contraction And VolatilityDeclining and volatile revenue undermines scale benefits and makes it harder to convert strong gross margins into operating profits. Persistent top-line weakness increases pressure on margins per unit, slows cash-flow improvement, and weakens negotiating leverage with partners and payers over the medium term.
CANbridge Pharmaceuticals Inc. News
1228 FAQ
What was CANbridge Pharmaceuticals Inc.’s price range in the past 12 months?
CANbridge Pharmaceuticals Inc. lowest stock price was HK$0.96 and its highest was HK$3.50 in the past 12 months.
What is CANbridge Pharmaceuticals Inc.’s market cap?
CANbridge Pharmaceuticals Inc.’s market cap is HK$1.19B.
When is CANbridge Pharmaceuticals Inc.’s upcoming earnings report date?
CANbridge Pharmaceuticals Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 26 days.
How were CANbridge Pharmaceuticals Inc.’s earnings last quarter?
CANbridge Pharmaceuticals Inc. released its earnings results on Mar 30, 2026. The company reported -HK$0.095 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is CANbridge Pharmaceuticals Inc. overvalued?
According to Wall Street analysts CANbridge Pharmaceuticals Inc.’s price is currently Overvalued.
Does CANbridge Pharmaceuticals Inc. pay dividends?
CANbridge Pharmaceuticals Inc. does not currently pay dividends.
What is CANbridge Pharmaceuticals Inc.’s EPS estimate?
CANbridge Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CANbridge Pharmaceuticals Inc. have?
CANbridge Pharmaceuticals Inc. has 597,443,360 shares outstanding.
What happened to CANbridge Pharmaceuticals Inc.’s price movement after its last earnings report?
CANbridge Pharmaceuticals Inc. reported an EPS of -HK$0.095 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.382%.
Which hedge fund is a major shareholder of CANbridge Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in HK:1228
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CANbridge Pharmaceuticals Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
696.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.19%
Trailing 12-Months
Company Description
CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―